Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
1.
Rev. bras. oftalmol ; 79(1): 59-62, Jan.-Feb. 2020. tab, graf
Article in English | LILACS | ID: biblio-1092665

ABSTRACT

Abstract Tolosa-Hunt syndrome is a painful ophthalmoplegia caused by non-specific granulomatous inflammation, corticoid-sensitive, of the cavernous sinus. The etiology is unknown. Recurrences are common. The diagnosis is made by exclusion, and a variety of other diseases involving the orbital apex, superior orbital fissure and cavernous sinus should be ruled out. This study reports a case of a 29-year-old woman, diagnosed with Tolosa-Hunt Syndrome, who presented ophthalmoparesis and orbital pain. She had poor response to corticotherapy and developed colateral effects, so she was treated with single infliximab dose immunosuppression, evolving total remission of the disease.


Resumo A Síndrome de Tolosa-Hunt é uma oftalmoplegia dolorosa causada por uma inflamação granulomatosa não específica, sensível a corticoides, do seio cavernoso. A etiologia é desconhecida. Recorrências são comuns. O diagnóstico é feito por exclusão, devendo ser descartada uma variedade de outras doenças que envolvem o ápice orbitário, fissura orbitária superior e seio cavernoso. O presente estudo trata-se de um relato de caso de uma paciente de 29 anos, diagnosticada com Síndrome de Tolosa-Hunt, que apresentou paresia e dor em região orbital. Obteve resposta pouco efetiva a corticoterapia e desenvolveu efeitos colaterais, por isso foi tratada com dose única de infliximabe, evoluindo com remissão total da doença.


Subject(s)
Humans , Female , Adult , Tolosa-Hunt Syndrome/drug therapy , Infliximab/administration & dosage , Infliximab/therapeutic use , Pain/drug therapy , Remission Induction , Prednisolone/adverse effects , Prednisone/adverse effects , Single Dose , Ophthalmoplegia/drug therapy , Tolosa-Hunt Syndrome/diagnosis
2.
Braz. j. otorhinolaryngol. (Impr.) ; 83(6): 633-639, Nov.-Dec. 2017. tab, graf
Article in English | LILACS | ID: biblio-889315

ABSTRACT

Abstract Introduction: A combination of antihistamines and oral corticosteroids is often used to treat acute symptoms of allergic rhinitis. Objective: To evaluate safety and efficacy of desloratadine plus prednisolone in the treatment of acute symptoms of children (2-12 years) with allergic rhinitis, and to compare it to dexchlorpheniramine plus betamethasone. Methods: Children with moderate/severe persistent allergic rhinitis and symptomatic (nasal symptoms score [0-12] ≥ 6) were allocated in a double-blind, randomized fashion to receive dexchlorpheniramine plus betamethasone (n = 105; three daily doses) or desloratadine plus prednisolone (n = 105; single dose followed by two of placebo) for 7 days. At the beginning and end of the evaluation, the following were obtained: nasal symptoms score, extra nasal symptoms score, peak nasal inspiratory flow, blood biochemistry, and electrocardiogram. Ninety-six children of the dexchlorpheniramine plus betamethasone group and 98 of the desloratadine plus prednisolone group completed the protocol. Results: The two groups were similar regarding initial and final nasal symptoms scores, extra nasal symptoms scores and peak nasal inspiratory flow. A drop of 76.4% and 79.1% for nasal symptoms score, 86.0% and 79.2% for extra nasal symptoms score, as well as an increase of 25.2% and 24.3% for peak nasal inspiratory flow occurred for those treated with desloratadine plus prednisolone and dexchlorpheniramine plus betamethasone, respectively. There were no significant changes in blood chemistry. Sinus tachycardia was the most frequent electrocardiogram change, but with no clinical significance. Drowsiness was reported significantly more often among those of dexchlorpheniramine plus betamethasone group (17.14% × 8.57%, respectively). Conclusion: The desloratadine plus prednisolone combination was able to effectively control acute symptoms of rhinitis in children, improving symptoms and nasal function. Compared to the dexchlorpheniramine plus betamethasone combination, it showed similar clinical action, but with a lower incidence of adverse events and higher dosing convenience.


Resumo Introdução: A associação entre anti-histamínicos e corticosteroides orais é frequentemente empregada no tratamento de sintomas agudos de rinite alérgica. Objetivo: Avaliar a segurança e eficácia da associação desloratadina + prednisolona no tratamento de sintomas agudos de crianças (2-12 anos) com rinite alérgica e compará-las com as da associação dexclorfeniramina + betametasona. Método: Crianças com rinite alérgica persistente moderada/grave e sintomáticas (escore de sintomas nasais [0-12] ≥ 6) foram alocadas de modo duplo-cego e randômico para receber dexclorfeniramina + betametasona (n = 105; três doses diárias) ou desloratadina + prednisolona (n = 105; dose única seguida por duas de placebo) por 7 dias. No início e no fim da avaliação foram obtidos: escore de sintomas nasais, escore de sintomas extranasais, pico de fluxo inspiratório nasal, bioquímica sanguínea e eletrocardiograma. Do total, 96 crianças do grupo dexclorfeniramina + betametasona e 98 do grupo desloratadina + prednisolona concluíram o protocolo. Resultados: Os dois grupos foram iguais com relação ao escore de sintomas nasais, escore de sintomas nasais extranasais e pico de fluxo inspiratório nasal iniciais e finais. Observou-se queda de 76,4% e 79,1% nos escores para escore de sintomas nasais, de 86,0% e 79,2% para escore de sintomas extranasais, assim como incremento de 25,2% e de 24,3% para o pico de fluxo inspiratório nasal para os grupos desloratadina + prednisolona e dexclorfeniramina + betametasona, respectivamente. Não houve alterações significativas da bioquímica sanguínea. Taquicardia sinusal foi a alteração do eletrocardiograma mais encontrada, mas sem significância clínica. Sonolência foi significantemente mais referida entre os tratados com dexclorfeniramina + betametasona do que entre os desloratadina + prednisolona (8,57% × 17,14%, respectivamente). Conclusão: A associação desloratadina + prednisolona foi capaz de controlar efetivamente os sintomas agudos de rinite em crianças, melhorou sintomas e a função nasal. Na comparação com a associação dexclorfeniramina + betametasona, demonstrou ação clínica semelhante, mas com menor incidência de eventos adversos e maior comodidade posológica.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Prednisolone/administration & dosage , Loratadine/analogs & derivatives , Rhinitis, Allergic/drug therapy , Glucocorticoids/administration & dosage , Time Factors , Severity of Illness Index , Betamethasone/administration & dosage , Betamethasone/adverse effects , Prednisolone/adverse effects , Peak Expiratory Flow Rate , Double-Blind Method , Reproducibility of Results , Treatment Outcome , Loratadine/administration & dosage , Loratadine/adverse effects , Statistics, Nonparametric , Histamine H1 Antagonists, Non-Sedating/administration & dosage , Histamine H1 Antagonists, Non-Sedating/adverse effects , Drug Combinations , Glucocorticoids/adverse effects
5.
Arq. gastroenterol ; 53(3): 206-211, tab
Article in English | LILACS | ID: lil-787345

ABSTRACT

ABSTRACT The main objectives of clinical therapy in Crohn's disease are clinical and endoscopic remission without the use of corticosteroids for long periods of time, prevention of hospitalization and surgery, and improvement of quality of life. The main limitation of drug therapy is the loss of response over the long term, which makes incorporation of new drugs to the therapeutic arsenal necessary. This review analyses the main drugs currently used in clinical treatment of Crohn's disease.


RESUMO Os principais objetivos da terapia clínica na doença de Crohn são a remissão clínica e endoscópica por tempo prolongado, sem o uso de corticosteroides, além de evitar hospitalizações e cirurgias, e melhorar a qualidade de vida. A principal limitação da terapêutica medicamentosa é a perda de reposta a longo prazo, o que faz com que a incorporação de novas drogas ao arsenal terapêutico seja necessária. Esta revisão aborda os principais medicamentos utilizados atualmente no tratamento clínico da doença de Crohn.


Subject(s)
Humans , Biological Therapy/standards , Crohn Disease/therapy , Immunosuppressive Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Aminosalicylic Acid/administration & dosage , Aminosalicylic Acid/therapeutic use , Prednisolone/adverse effects , Prednisolone/therapeutic use , Crohn Disease/drug therapy , Dose-Response Relationship, Drug , Immunosuppressive Agents/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use
6.
JPAD-Journal of Pakistan Association of Dermatologists. 2015; 25 (1): 23-29
in English | IMEMR | ID: emr-171485

ABSTRACT

To compare the adverse effects of low-dose oral prednisolone and oral mini pulse dexamethasone in patients of vitiligo. A clinical trial was carried out from January 2013 to December 2013. Total sixty patients of vitiligo were enrolled and 30 of group A patients were treated with low dose oral prednisolone [0.3 mg/kg body weight] daily and 30 of group B patients were treated with oral dexamethasone pulse therapy [10 mg per week] for 16 weeks. During 12 week follow-up, increased body weight, headache, dyspepsia and fatigue were more frequent in group A as compared to group B. Similarly, in group A other side effects noted were acne [33.3%], mooning of face [26.6%], striae [26.6%], hypertrichosis 13.2%, purpura [6.7%] and among the female patients, menstrual abnormality [71.4%] whereas in group B, no patient developed these problems from baseline to follow-up period [p<0.05] Low dose oral prednisolone was found to be associated with more adverse effects than oral dexamethasone pulse therapy in treating vitiligo


Subject(s)
Adult , Female , Humans , Male , Prednisolone/adverse effects , Prednisolone/administration & dosage , Dexamethasone/adverse effects , Dexamethasone/administration & dosage
7.
IJRM-Iranian Journal of Reproductive Medicine. 2012; 10 (4): 363-372
in English | IMEMR | ID: emr-132389

ABSTRACT

Osteoporosis is a chronic disease characterized by a decrease in bone mineral density [BMD] and corruption of the microarchitectural structure of bone tissue. It was investigated whether methylprednisolone had a favorable effect on osteoporotic bone tissue in Oophorectomy induced osteoporotic rats whose endogenous adrenaline levels are suppressed with metyrosine. Bone Mineral Density, number of osteoblast-osteoclast, bone osteocalcin levels and alkaline phosphatase [ALP] measurements were performed. Obtained results were compared with that of alendronate. Oophorectomy induced osteoporosis was exacerbated by methylprednisolone. Alentronate prevented ovariectomised induced osteoporosis, but it couldn't prevent methylprednisolone +ovariectomised induced osteoporosis in rats. Combined treatment with methylprednisolon and metyrosine was the best treatment for preventing osteoporosis but metyrosine alone couldn't prevent osteoporosis in ovariectomised rats


Subject(s)
Female , Animals, Laboratory , Methyltyrosines , Rats , Osteoclasts/drug effects , Prednisolone , Prednisolone/adverse effects , Drug Combinations , Ovariectomy/adverse effects , Osteoblasts/drug effects , Bone Density/drug effects , Methylprednisolone/adverse effects , Methylprednisolone , Osteocalcin/drug effects , Alkaline Phosphatase , Alendronate , Treatment Outcome
8.
JAMC-Journal of Ayub Medical College-Abbotabad-Pakistan. 2011; 23 (1): 80-83
in English | IMEMR | ID: emr-132416

ABSTRACT

Chemotherapy used for malignant diseases may produce severe neutropenia in first cycle which may compel for dose modification and early termination of therapy. This descriptive cross sectional study was planned to see the frequency and severity of neutropenia after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolon in patients of diffuse large B-cell non Hodgkin's lymphoma presenting at Oncology Department Combined Military Hospital Rawalpindi from August 2009 to July 2010. Thirty patients of diffuse large B-cell non Hodgkin's lymphoma diagnosed on lymph node biopsy presenting for the first time at Oncology Department Combined Military Hospital Rawalpindi were included. They were admitted in the ward and evaluated with history, physical examination and staging investigations. Patients were then planned for first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, and vincristine with prednisolon. After the first cycle of chemotherapy they were monitored for expected neutropenia in the ward. The neutrophil counts were repeated on days 7 and 10 following chemotherapy. Neutropenia was graded as defined in the operational definition and all the data was entered on a specially designed data card. As much as 3.3% of patients suffered from grade IV neutropenia [absolute neutrophil count of <0.5x10[9]/L], 3.3% had grade III neutropenia [absolute neutrophil count of 0.5x10[9]/L- 0.9x10[9]/L], 6.6% had Grade II neutropenia [absolute neutrophil count 1.0x10[9]/L-1.4x10[9]/L and 10% had Grade I neutropenia [absolute neutrophil count 1.5x10[9]/L-1.9x10[9]/L. Overall 23.2% suffered from neutropenia of all grades post 1st cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolon in diffuse large B-cell non Hodgkin's lymphoma. Further studies are required to find the risk factors to predict this complication in our population


Subject(s)
Humans , Neutropenia , Lymphoma, Non-Hodgkin , Drug Therapy/adverse effects , Cyclophosphamide/adverse effects , Cyclophosphamide , Doxorubicin/adverse effects , Doxorubicin , Vincristine/adverse effects , Vincristine , Prednisolone/adverse effects , Prednisolone , Cross-Sectional Studies
9.
Indian J Pediatr ; 2009 Dec; 76(12): 1237-1239
Article in English | IMSEAR | ID: sea-142450

ABSTRACT

Objective. To observe the influence of prednisolone treatment on bone mineral density (BMD) in children with idiopathic nephrotic syndrome. Methods. Duel-energy X-ray absorptiometry of lumbar spine (L1-L4) was performed on 40 patients (18 first episode and 22 relapsers) of steroid sensitive idiopathic nephrotic syndrome. Results. Patients of first episode and relapsers had comparable values of mean age, weight, height, body mass index, serum calcium, phosphate, spine area, bone mineral content (BMC) and BMD. Relapsing nephrotic syndrome patients received significantly higher mean total cumulative dose of prednisolone in comparison to first episode (p<0.001). The BMD Z-scores were normal in 39 of 40 (97.5%) patients. On regression analysis, it was found that both BMC and BMD did not correlate with cumulative dose of prednisolone, when other co-variants such as age, weight, height and spine area were adjusted. Conclusion. Bone mineral density in steroid sensitive nephrotic syndrome is unaffected by cumulative dose of prednisolone therapy both in first episode as well as relapser group of patients.


Subject(s)
Absorptiometry, Photon , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Bone Demineralization, Pathologic/chemically induced , Bone Demineralization, Pathologic/etiology , Bone Density/drug effects , Case-Control Studies , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Humans , India , Male , Nephrotic Syndrome/complications , Nephrotic Syndrome/drug therapy , Prednisolone/administration & dosage , Prednisolone/adverse effects , Recurrence , Regression Analysis
10.
Medical Principles and Practice. 2009; 18 (5): 414-417
in English | IMEMR | ID: emr-123156

ABSTRACT

It was the aim of this study to report 3 rare fatal cases of strongyloidiasis in Kuwait renal transplant patients. All 3 cases received allografts from cadaveric donors of Asian origin, the first 2 from an Indian [transplanted on the same day] and the third from a Bangladeshi. In all 3 cases, Strongyloides stercoralis larvae were first isolated from bronchoalveolar lavage. All 3 patients were on immunosuppressive therapy which included prednisolone, thereby leading to the hyperinfection syndrome. All patients presented with gastrointestinal symptoms [abdominal pain, vomiting, diarrhea, constipation and paralytic ileus], as well as pulmonary symptoms [cough, dyspnea and blood-stained sputum]. Albendazole 800 mg twice daily orally was started. Cyclosporine A was started after discontinuing prograf. The patients continued to deteriorate with a fall in blood pressure and platelets. All 3 patients died from adult respiratory distress syndrome following hyperinfection with S. stercoralis. Hyperinfection with S. stercoralis is a rare but preventable complication of immunosuppressive therapy. A high index of suspicion is required for the diagnosis of this infection. Persistent examination of sputum, bronchial washings and upper intestinal aspirates should be done as part of surveillance following cadaveric renal transplantation. Adult respiratory distress syndrome is indeed a red flag in patients who are on steroids, not on cyclosporine and receiving a kidney from donors in endemic countries of S. stercoralis


Subject(s)
Humans , Male , Female , Immunocompromised Host , Tissue Donors , Respiratory Distress Syndrome , Albendazole , Immunosuppressive Agents/adverse effects , Prednisolone/adverse effects , Cyclosporine/adverse effects , Cyclosporine , Cadaver
11.
Iranian Journal of Clinical Infectious Diseases. 2009; 4 (4): 238-240
in English | IMEMR | ID: emr-106525

ABSTRACT

Cytomegalovirus [CMV] pneumonia is one of the most important infections in immunocompromised host. Immunosuppressive therapy plays a major role in reactivation of CMV. The patient was a 56-year old lady, known case of chronic lymphocytic leukemia [CLL], had been taking prednisolone and chlorambucil, who presented with dyspnea and productive cough. After bronchoalveolar lavage [BAL], transbronchial lung biopsy [TBLB] and CT-guided biopsy, CMV pneumonia was diagnosed. CMV should be suspected as a cause of pneumonia in immunocompromised patient and diagnosis may require invasive procedures


Subject(s)
Humans , Female , Cytomegalovirus Infections , Pneumonia , Immunocompromised Host , Immunosuppression Therapy/adverse effects , Leukemia, Lymphocytic, Chronic, B-Cell , Prednisolone/adverse effects , Prednisolone , Chlorambucil/adverse effects , Chlorambucil
12.
IJKD-Iranian Journal of Kidney Diseases. 2008; 2 (3): 154-159
in English | IMEMR | ID: emr-102834

ABSTRACT

We measured bone mineral density [BMD] before and after transplantation to determine the frequency and severity of preoperative and postoperative osteoporosis and compare them with the BMD in healthy individuals. We determined the BMD at the lumbar spine and femoral levels in 22 men and 18 women who were on long-term dialysis in Yazd, Iran, and a group of kidney transplant recipients including 43 men and 18 women. They were compared with each other and healthy individuals studied in a recent study in Iran. Factors potentially associated with alterations of the BMD were studied in each group. The frequency of osteoporosis in the vertebrae and femoral neck was higher in the kidney transplant recipients than the healthy population [21.3% versus 4.9%; P = .001; odds ratio, 5 and 9.8% versus 2.4%; P = .02; odds ratio, 5.4, respectively] but not significantly different from those in the patients on dialysis [17.9% and 17.5%, respectively]. In transplantation group, multivariate analysis showed that there was a significant negative correlation between the lumbar BMD and the cumulative prednisolone dose [r = -0.36, P = .003]. No correlation was found between BMD of lumbar or femoral neck and the body mass index, age, and cumulative cyclosporine level. Osteoporosis is more frequent in patients on dialysis and kidney transplant recipient than in general population. However, there is no difference in osteoporosis frequency between transplanted patients and those on dialysis. In the lumbar spine, a higher cumulative prednisolone dose results in decreased BMD among kidney transplant recipients


Subject(s)
Humans , Male , Female , Kidney Transplantation/pathology , Renal Dialysis , Osteoporosis/epidemiology , Lumbar Vertebrae , Femur , Prednisolone/adverse effects , Absorptiometry, Photon
13.
Pakistan Journal of Medical Sciences. 2008; 24 (4): 612-613
in English | IMEMR | ID: emr-89588

ABSTRACT

Unilateral vocal cord patsy is not uncommon. The common aetiologies include post neck operation particularly thyroid surgery, trauma to the neck, primary or metastatic neck node or bronchogenic carcinoma. We present a case of a 61 years old Malay gentleman who was diagnosed to have lymphoma and started on usual chemotherapy regime for lymphoma. Later on, he developed unilateral vocal cord palsy. Possible aetiologies were discussed


Subject(s)
Humans , Male , Vocal Cord Paralysis/diagnostic imaging , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/drug therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal , Cyclophosphamide/adverse effects , Cyclophosphamide , Doxorubicin/adverse effects , Doxorubicin , Vincristine/adverse effects , Vincristine , Prednisolone/adverse effects , Prednisolone
14.
Article in English | IMSEAR | ID: sea-40986

ABSTRACT

A 34-year-old Thai man presented with a two years history of progressively enlarged lepromatous leprosy like nodules and plaques on his back, chest, and scalp. Skin biopsy showed diffuse nonnecrotizing granulomatous inflammation with numerous multinucleated giant cells, lymphocytes, and plasma cells infiltration. The missed diagnosis of leprosy was made and was treated with antilepromatous drugs for one year. After repeated skin biopsy, the diagnosis was compatible with sarcoidosis. He was treated with prednisolone 40 mg per day for two weeks. The lesions gradually decreased in size and were controlled with prednisolone 10 mg per day.


Subject(s)
Adult , Glucocorticoids/adverse effects , Humans , Leprosy, Lepromatous/diagnosis , Male , Prednisolone/adverse effects , Sarcoidosis/diagnosis , Skin Diseases/diagnosis
15.
JLUMHS-Journal of the Liaquat University of Medical Health Sciences. 2007; 6 (1): 8-12
in English | IMEMR | ID: emr-83263

ABSTRACT

To determine the frequency of glaucoma in children with vernal conjunctivitis using topical steroids, referred to a tertiary eye care centre. Descriptive case series. This study was carried out at department of Ophthalmology, Liaquat University Eye Hospital Hyderabad, Sindh - Pakistan, from July 2002 to December 2004 [Thirty months]. A total of 200 patients with chronic allergic conjunctivitis using topical steroids [Betamethasone, Dexamethasone, Prednisolone] for more than six months were examined. A thorough examination including visual acuity, Goldmann applanation tonometry, Schiot'z tonometry, Gonioscopy, slit lamp examination and dilated Ophthalmoscopy were performed. Out of 200 patients examined, fifteen [7.5%] were found having raised intraocular pressure [secondary glaucoma] due to prolonged use of topical steroids. The rise of intraocular pressure was bilateral in three patients [1.5%], and unilateral in twelve patients [6.0%]. The topical steroids were discontinued. One patient with vernal conjunctivitis using topical steroids since more than two years developed left optic disc pallor with constriction of visual field, and posterior sub capsular cataract. The intraocular pressure was not controlled by ocular hypotensive agents, and glaucoma filtration surgery was advised. This study identifies the risk of intraocular pressure elevation in patients with allergic conjunctivitis, using topical steroids for longer periods. Long term use of topical and systemic steroids produces secondary open angle glaucoma similar to chronic simple glaucoma. We can conclude that Dexamethasone and Prednisolone are possible risk factors for producing glaucoma


Subject(s)
Humans , Male , Female , Glaucoma/chemically induced , Conjunctivitis, Allergic , Prednisolone/adverse effects , Intraocular Pressure , Betamethasone/adverse effects , Child , Dexamethasone/adverse effects
16.
Indian J Chest Dis Allied Sci ; 2006 Jan-Mar; 48(1): 67-9
Article in English | IMSEAR | ID: sea-29734

ABSTRACT

Strongyloides stercoralis is a nematode endemic in tropical and subtropical regions. In immunocompetent subjects, pulmonary disease caused by the parasite is unremarkable but the same can be life threatening in immunocompromised subjects. Though described in literature it is rarely seen in Indian subjects. We report a patient with ARDS due to Strongyloides stercoralis complicating non-Hodgkin's lymphoma with neutropenia.


Subject(s)
Aged , Albendazole/therapeutic use , Animals , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antiparasitic Agents/therapeutic use , Cyclophosphamide/adverse effects , Doxorubicin/adverse effects , Fatal Outcome , Humans , Ivermectin/therapeutic use , Lymphoma, Non-Hodgkin/complications , Male , Multiple Organ Failure/etiology , Neutropenia/etiology , Prednisolone/adverse effects , Respiratory Distress Syndrome/etiology , Strongyloides stercoralis/isolation & purification , Strongyloidiasis/complications , Vincristine/adverse effects
19.
Article in English | IMSEAR | ID: sea-90682

ABSTRACT

We report a case of palmar plantar erythrodysesthesia (PPE) in a case of acute lymphoblastic leukemia treated with VALP regime. The treating physician must be aware of this uncommon complication of chemotherapeutic agents to avoid unnecessary investigations.


Subject(s)
Adolescent , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Doxorubicin/adverse effects , Drug Eruptions , Erythema/chemically induced , Female , Foot Dermatoses/chemically induced , Hand Dermatoses/chemically induced , Humans , Paresthesia/chemically induced , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Prednisolone/adverse effects , Vincristine/adverse effects
20.
J Indian Med Assoc ; 2004 Dec; 102(12): 688-90, 692, 694
Article in English | IMSEAR | ID: sea-99955

ABSTRACT

The uneventful response to chemotherapy in leprosy is marked by clinically disturbing episodes encountered in 20-30% of patients and these phenomena are called "reactions". Generally they are classified as reversal reaction (type-1) and erythema nodosum leprosum (type-2). The cutaneous menifestations are: (1) Type-2 reactions in LL, BL types constituting erythema nodosum leprosum, erythema multiforme, erythema necroticans, subcutaneous nodules, lepromatous exacerbation. (2) Type-1 reactions in borderline and tuberculoid leprosy. The other manifestations include: Acute neuritis, lymphadenitis, arthritis, oedema of the hands and feet, ocular lesions, etc. Sequelae of reactions are: Paralytic deformities, non-paralytic deformities, extensive scarring and renal damage. A simple guideline to identify the risk-prone cases has been narrated. Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes.


Subject(s)
Arthritis/chemically induced , Cicatrix/chemically induced , Clofazimine/adverse effects , Dose-Response Relationship, Drug , Drug Therapy/adverse effects , Edema/chemically induced , Erythema/chemically induced , Erythema Nodosum/chemically induced , Foot/pathology , Glucocorticoids/adverse effects , Hand/pathology , Humans , Hypersensitivity/etiology , Immunosuppressive Agents/adverse effects , Leprosy/drug therapy , Lymphadenitis/chemically induced , Neuritis/chemically induced , Paralysis/chemically induced , Prednisolone/adverse effects , Skin/drug effects , Thalidomide/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL